文献速递脑血管病外科神经重症

静脉干细胞治疗高级别动脉瘤性蛛网膜下腔出血:病例报告与文献综述

Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage: Case Report and Literature Review.
PubMed 文献 · World Neurosurg · 2019-04-11

本文报告一例80岁男性高级别动脉瘤性蛛网膜下腔出血患者,在出血后第3天接受静脉骨髓来源异体间充质干细胞输注,6个月时改良Rankin量表评分为3,恢复优于预期。结合动物研究结果,作者认为该初步病例支持开展进一步临床试验。

要点

  • 首例人类静脉间充质干细胞治疗动脉瘤性SAH的病例报告
  • 80岁男性Hunt-Hess 5级、WFNS 5级,经脑室外引流和弹簧圈栓塞治疗
  • 出血后第3天输注骨髓来源异体间充质干细胞,6个月mRS为3

核心结论

  • 这是首例使用间充质干细胞治疗动脉瘤性蛛网膜下腔出血的人类病例,初步结果鼓励进一步开展临床试验。

研究设计与样本

  • 病例报告及文献综述,报告一例80岁男性动脉瘤性SAH患者接受静脉骨髓来源异体间充质干细胞输注。

主要发现

  • 患者初始Hunt-Hess 5级、WFNS 5级,CT示SAH伴脑积水,源于基底动脉尖动脉瘤破裂。
  • 患者接受脑室外引流置入和动脉瘤弹簧圈栓塞,出血后第3天接受静脉骨髓来源异体间充质干细胞输注。
  • 6个月时改良Rankin量表评分为3,恢复优于预期。

关键数值与推荐

  • 动脉瘤性SAH死亡率高达30%-40%,多数患者初始Hunt-Hess级别高。
  • 动物研究显示间充质干细胞可改善功能神经恢复并减少脑损伤体积。

临床怎么用

  • 该病例为高级别动脉瘤性SAH的干细胞治疗提供了初步人类经验,但尚不能改变临床实践。
  • 间充质干细胞治疗动脉瘤性SAH的作用尚不明确,需更多临床试验验证。

局限性

  • 仅为单例病例报告,无法确定因果关系或疗效。
  • 人类卒中研究有限,干细胞治疗动脉瘤性SAH的角色仍不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30%-40%) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuroregenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH. CLINICAL PRESENTATION: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow-derived allogeneic MSCs on day 3 postbleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months. CONCLUSIONS: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional clinical trials.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Brunet MC, Chen SH, Khandelwal P, et al. Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid Hemorrhage: Case Report and Literature Review. World Neurosurg. 2019. PMID: 30981798. doi:10.1016/j.wneu.2019.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。